Move the pharmaceutical factory into space?

 In recent years, the vigorous development of the pharmaceutical industry has provided a good guarantee for people's health
.
So is it possible to move biomedicine into space? It is reported that China’s space medicine research plan has begun to take shape.
According to statistics, the International Space Station has conducted about 3,000 scientific researches in various disciplines in more than 20 years of orbit, of which life sciences and biotechnology fields account for a relatively high proportion
.
Among them, the news from the investment community on December 20, 2021, Rocket (Taicang) Aerospace Technology Co.
, Ltd.
("Rocket") completed a round of financing of tens of millions of angels and plans to move biomedicine into space
.
It is understood that the Rocket Group has built a "space biology laboratory" around the core capabilities of launch vehicles to provide commercial space technology products and services for the biomedical industry
.
The Rocket Group’s plan is to provide flight-oriented, highly reliable and rapid response launch services, and to integrate industry chain resources to quickly achieve commercial closed loops.
Hospital"
.
Rocket Group’s current round of financing was led by the Hainan 100 billion Fund, local government industry fund Suzhou Guofa Venture Capital, and old shareholder Shanghai Huo Lei also participated in the investment.
This is Rocket Group’s second round of financing this year
.
According to the Rockets, the introduction of local government industry funds in this round of financing will help Taicang High-tech Zone to build a 50 billion-level biomedical industry cluster
.
Up to now, Rocket Group has signed cooperation agreements with Shanghai Jiaotong University, Ruijin Hospital and other units to jointly develop the space biomedicine market
.
In addition, in September of this year, the Rocket General Assembly and General Test Base landed in Taicang High-tech Zone.
So far, it has formed a dual-base pattern of Beijing and Shanghai R&D Centers, Taicang Rocket General Assembly General Test Base and Suzhou Space Biological Experiment Base
.
It is understood that behind some new drugs, there are also contributions from space experiments
.
For example, Merck’s Keytruda (Keytruda) development, in order to study the key variables that affect crystal growth, in 2019, its researchers cooperated with the International Space Station to conduct a crystallization experiment using the K drug in the SpaceX Commercial Supply Service No.
10 space mission.
Microgravity experiments have studied the effects of sedimentation rate and temperature gradient on crystallization purification
.
The results found that under microgravity conditions, settlement and convection are reduced, and the resulting crystalline suspension has a lower viscosity and is more uniform than the ground control
.
It is understood that China will follow the principle of easy to difficult in space medicine research, and is currently trying to start with microbiological research, astronaut health research, and new drug research and development
.
According to the industry, the completion of China's space station will provide a new innovative carrier for the development of Chinese medicine, help the overall innovation and promotion of Chinese medicine, and bring space technology to benefit human life and health
.